Healthcare Industry News: Mobetron
News Release - November 8, 2007
First Mobetron in Germany, 24th Worldwide: Renowned CDT Breast Cancer Center in Cologne Selects IntraOp Medical's Mobetron Device for Advanced Intraoperative Electron Radiation TherapySUNNYVALE, Calif.--(HSMN NewsFeed)--IntraOp Medical Corporation (OTCBB: IOPM ), a provider of innovative technology solutions for the treatment and eradication of cancer, announced today that the CDT Strahleninstitut Koln, a renowned breast cancer center in Cologne, Germany has selected Mobetron for advanced breast cancer treatment. Mobetron directly delivers intraoperative electron radiation therapy (“IOERT”) to patients as they undergo surgery in a highly safe and efficient manner. This order comes on the heels of a significant patent defense in Germany; the judgment was ruled in IntraOp’s favor.
The CDT Strahleninstitut Koln is a leading breast cancer treatment facility in Cologne, Germany. The center uses a comprehensive, multidisciplinary approach to cancer care, integrating surgery, radiation therapy, and chemotherapy treatments, as appropriate. Leveraging the most advanced medical treatment available, CDT Strahleninstitut Koln has been using radiotherapy for more than 80 years and was the first facility in Germany to perform lumpectomies; it will now be the first private institution in the country to provide IOERT in the operating room.
With Mobetron, radiation and surgical oncologists can pinpoint the exact area that requires radiation and immediately deliver high doses directly to the affected tissue during cancer surgery. Key patient benefits of this early and powerful start to radiation therapy include: better local tumor control, shorter treatment cycles and fewer side effects. Studies show that increasing local control in breast cancer will also lead to improvement in survival.
Dr. Hajo Jennissen, principal, CDT Strahleninstitut Koln, said, “For most women, a diagnosis of breast cancer is devastating—both emotionally and physically. In Germany this year, 46,000 women will be diagnosed with the disease; 19,000 of whom will most likely die. Breast cancer demands the most advanced medical treatment available, so we are very pleased be able to now offer IntraOp’s Mobetron device—along with new hope—to breast cancer patients in our country.”
John Powers, CEO of IntraOp Medical said, “It is exciting to see the growth and acceptance of Mobetron in new countries, knowing the positive impact it will have on cancer patients, not only in Germany, but in neighboring European countries. We are looking forward to working closely with the CDT in Cologne to provide the most advanced medical technology available to effectively and efficiently treat breast cancer.”
For more information about the CDT Strahleninstitut Koln, please visit: http://www.strahleninstitut.de/.
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.